These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 26054089)
1. [Mogamulizumab for the treatment of ATL and PTCL]. Tsukasaki K Gan To Kagaku Ryoho; 2015 May; 42(5):553-7. PubMed ID: 26054089 [No Abstract] [Full Text] [Related]
2. Mogamulizumab for the treatment of T-cell lymphoma. Makita S; Tobinai K Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848 [TBL] [Abstract][Full Text] [Related]
3. Recent advances in the treatment of adult T-cell leukemia-lymphomas. Utsunomiya A; Choi I; Chihara D; Seto M Cancer Sci; 2015 Apr; 106(4):344-51. PubMed ID: 25613789 [TBL] [Abstract][Full Text] [Related]
5. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. Tobinai K; Takahashi T; Akinaga S Curr Hematol Malig Rep; 2012 Sep; 7(3):235-40. PubMed ID: 22538464 [TBL] [Abstract][Full Text] [Related]
6. Dosing of a phase I study of KW-0761, an anti-CCR4 antibody, for adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. Suzuki R J Clin Oncol; 2010 Aug; 28(23):e404-5; author reply e406. PubMed ID: 20566994 [No Abstract] [Full Text] [Related]
7. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310 [TBL] [Abstract][Full Text] [Related]
8. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis. Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073 [TBL] [Abstract][Full Text] [Related]
9. [Development of an anti-CCR4 antibody, mogamulizumab, the first approved antibody made by POTELLIGENT(®) technology]. Ishii T Nihon Yakurigaku Zasshi; 2013 Oct; 142(4):167-71. PubMed ID: 24107520 [No Abstract] [Full Text] [Related]
10. [Development of mogamulizumab and establishment of an optimal therapy based on genomic biomarkers: from the academic viewpoint]. Iida S; Ishida T; Ueda R Yakugaku Zasshi; 2015; 135(5):663-9. PubMed ID: 25948299 [TBL] [Abstract][Full Text] [Related]
11. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026 [TBL] [Abstract][Full Text] [Related]
12. Loss of CCR4 antigen expression after mogamulizumab therapy in a case of adult T-cell leukaemia-lymphoma. Ohno N; Kobayashi S; Ishigaki T; Yuji K; Kobayashi M; Sato K; Watanabe N; Tojo A; Uchimaru K Br J Haematol; 2013 Dec; 163(5):683-5. PubMed ID: 23998261 [No Abstract] [Full Text] [Related]
13. Molecular analysis of loss of CCR4 expression during mogamulizumab monotherapy in an adult T cell leukemia/lymphoma patient. Taguchi M; Imaizumi Y; Sasaki D; Higuchi T; Tsuruda K; Hasegawa H; Taguchi J; Sawayama Y; Imanishi D; Hata T; Yanagihara K; Yoshie O; Miyazaki Y Ann Hematol; 2015 Apr; 94(4):693-5. PubMed ID: 25338968 [No Abstract] [Full Text] [Related]
14. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma. Winsett FT; Lewis DJ; Duvic M Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726 [TBL] [Abstract][Full Text] [Related]